Eric Hsu
2021
In 2021, Eric Hsu earned a total compensation of $398.1K as Senior Vice President, PreClinical R&D at InMed Pharmaceuticals.
Compensation breakdown
| Bonus | $84,659 |
|---|---|
| Option Awards | $69,083 |
| Salary | $244,327 |
| Total | $398,069 |
Hsu received $244.3K in salary, accounting for 61% of the total pay in 2021.
Hsu also received $84.7K in bonus and $69.1K in option awards.
Rankings
In 2021, Eric Hsu's compensation ranked 11,177th out of 12,415 executives tracked by ExecPay. In other words, Hsu earned more than 10.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 11,177 out of 12,415 | 10th |
Division Manufacturing | 4,938 out of 5,505 | 10th |
Major group Chemicals And Allied Products | 2,199 out of 2,375 | 7th |
Industry group Drugs | 1,957 out of 2,096 | 7th |
Industry Pharmaceutical Preparations | 1,450 out of 1,546 | 6th |
Source: SEC filing on October 28, 2022.
Hsu's colleagues
We found three more compensation records of executives who worked with Eric Hsu at InMed Pharmaceuticals in 2021.
News
InMed Pharmaceuticals CEO Eric Adams' 2024 pay rises 13% to $415K
October 28, 2024
InMed Pharmaceuticals CEO Eric Adams' 2023 pay falls 22% to $368K
October 27, 2023
InMed Pharmaceuticals CEO Eric Adams' 2022 pay falls 36% to $468K
October 28, 2022
InMed Pharmaceuticals CEO Eric Adams' 2021 pay jumps 73% to $735K
October 28, 2021